The first angiogenesis inhibitors for cancer have now been approved by the FDA in the US
and in 28 other countries, including China. The majority of these are monotherapies that …

Background Angiogenesis is the process of neovascularization from pre-existing
vasculature and is involved in various physiological and pathological processes. Inhibitors …

Angiogenesis, the formation of new blood vessels, is required for many pathologic
processes, including invasive tumor growth as well as physiologic organ/tissue …

BACKGROUND: Adipose tissue produces both vascular growth factors and inhibitors. Since
obesity is associated with expansion of the capillary bed in regional adipose depots the …

Peptides have emerged as important therapeutics that are being rigorously tested in
angiogenesis-dependent diseases due to their low toxicity and high specificity. Since the …

Endostatin, a potent inhibitor of endothelial cell proliferation, migration, angiogenesis and
tumor growth, is proteolytically cleaved from the C-terminal noncollagenous NC1 domain of …

Angiogenesis is a multistep, complex and tightly regulated process that is necessary for
tumor growth and metastasis. Based on data of preclinical models, several antiangiogenic …

The anti-angiogenic effect of thrombospondin-1 has been shown to be mediated through
binding of the type-1 repeat (TSR) domain to the CD36 transmembrane receptor. We now …

A sequence of events in vascular and stromal cells maintained in a highly coordinated
manner regulates angiogenesis and tissue remodeling. These processes are mediated by …

Angiogenesis, the creation of neovasculature from native blood vessels, is a prerequisite for
many physiological and pathological processes. Recently, C-terminal tail fragments of …